Stories >> Healthcare

Avik Roy: How Drug Companies Stifle Competition With 'Product Hopping’

In 2014, drugmaker Forest Laboratories and its parent, Actavis, had a $28 billion problem. Actavis had spent that sum to acquire Forest and its portfolio of pharmaceutical products. The key patent for one of those drugs, a treatment for Alzheimer's disease called Namenda IR, was set to expire in July of 2015. Forest had been generating

Click to Link

Posted: May 21, 2024 Tuesday 05:33 PM